Welcome to our dedicated page for Opko Health news (Ticker: $OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Opko Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Opko Health's position in the market.
Rhea-AI Summary
SOPHiA GENETICS announced the implementation of MSK-ACCESS liquid biopsy to be commercially available for ordering by healthcare providers through BioReference and GenPath Oncology in 2024. The new offering aims to bring access to world-class liquid biopsy testing to BioReference's customers across the U.S., allowing for less invasive monitoring of cancers and expedited insights for precision medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SOPHiA GENETICS announced that BioReference Health, LLC will implement its technology and add MSK-ACCESS liquid biopsy to its test suite, making it the first laboratory globally to adopt this technology. The offering will be commercially available for ordering by healthcare providers through BioReference and its specialty division, GenPath Oncology, in 2024. The new liquid biopsy testing will enable the laboratory to analyze samples from a simple, non-invasive blood draw, allowing for less invasive monitoring of cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
OPKO Health, Inc. reports business highlights and financial results for the third quarter of 2023. ModeX Therapeutics awarded a $59 million contract from BARDA for the development of multispecific antibodies against viral infectious diseases. NGENLA approved in 48 markets, sales underway in 23 countries. New clinical data on RAYALDEE® presented at Kidney Week 2023. OPKO Biologics enters research collaboration agreement with Entera Bio Ltd. for oral peptide tablet formulations. BioReference Health implementing initiatives to return to profitability. Consolidated total revenues for Q3 2023 were $178.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
OPKO Health presented clinical data on RAYALDEE at the American Society of Nephrology Kidney Week. The data show that early and effective treatment of secondary hyperparathyroidism with RAYALDEE is associated with slower progression of chronic kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
-
Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) will report its operating and financial results for the three and nine months ended September 30, 2023 on November 6, 2023. The company's senior management will provide a business update and discuss results during a conference call and live webcast. Participants can pre-register for the conference call to receive a unique PIN for immediate access. The call can be accessed via phone or webcast, and replays will be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
-
Rhea-AI Summary
OPKO Health to present late-breaking clinical data on RAYALDEE at ASN Kidney Week
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
Rhea-AI Summary
NextPlat Corp announces e-commerce agreement with OPKO Health Europe to sell nutraceutical and veterinary products in China
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
-
Rhea-AI Summary
ModeX Therapeutics Inc. has been awarded a contract from BARDA to advance a platform and specific candidates to address viral infectious diseases. The contract includes an initial $59 million for the development of a next-generation MSTAR multispecific antibody for COVID-19. Additional funding of up to $109 million may be available for other viral pathogens. This collaboration strengthens ModeX's research and development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
-
Rhea-AI Summary
OPKO Health, Inc. reports business highlights and financial results for Q2 2023. Highlights include FDA approval of NGENLA for pediatric growth hormone deficiency and a $90 million milestone payment from Pfizer. NGENLA approved in 44 markets, sales underway in 18 countries. ModeX Therapeutics advancing antiviral and immune-oncology product pipeline. BioReference Health focused on cost reductions and profitability. Q2 revenues of $265.4 million, operating income of $7.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.57%
Tags
Rhea-AI Summary
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 3, 2023. The company's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on August 3rd beginning at 4:30 p.m. Eastern time. Participants are encouraged to pre-register for the conference call. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. A webcast of the call can also be accessed at OPKO’s Investor Relations page. A telephone replay and webcast replay will be available after the completion of the live conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
Opko Health Inc.
Nasdaq:OPK
OPK Rankings
OPK Stock Data
906.09M
331.18M
52.41%
25.07%
13.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
MIAMI
About OPK
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig